Rick Gonzalez, AbbVie CEO (Pablo Martinez Monsivais/AP Images)
AbbVie makes second deal in a week, betting $8.7B in cash on CNS biotech Cerevel
AbbVie said Wednesday evening it plans to pay $8.7 billion to acquire neuroscience drugmaker Cerevel Therapeutics in a deal that comes …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
